Two other DART molecules targeting T-cells and different TAA are currently evaluated by MacroGenics in collaboration with Servier (Suresnes, France), MGD006 (also encoded as S80880 by Servier), an anti-CD123 × CD3 in phase 1 (NCT02152956) for the treatment of acute myeloid leukemia (AML) and myelodysplatic syndrome and MGD007, an anti-gpA33 × CD3, in phase 1 for primary and metastatic human colorectal cancers (NCT02248805) (Figure 1). The gene discussed is GPA33; the disease is acute myeloid leukemia.